Bausch Health Companies Inc. Stock
$6.21
0.32%
day before yesterday
NYSE,
Sep 06, 10:10 pm CET
Bausch Health Companies Inc. Stock price
$6.21
+0.82
15.21%
1M
-3.02
32.72%
6M
-1.81
22.57%
YTD
-2.15
25.72%
1Y
-23.12
78.83%
3Y
-15.97
72.00%
5Y
-113.84
94.83%
10Y
NYSE,
Closing price Fri, Sep 06 2024
+0.02
0.32%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
| Market capitalization | $2.28b |
| Enterprise Value | $24.26b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 26.58 |
| EV/Sales (TTM) EV/Sales | 2.64 |
| P/S ratio (TTM) P/S ratio | 0.25 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 10.20% |
| Revenue (TTM) Revenue | $9.20b |
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
7 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
7 Analysts have issued a Bausch Health Companies Inc. forecast:
Buy
14%
Hold
57%
Sell
29%
Financial data from Bausch Health Companies Inc.
| Jun '24 |
+/-
%
|
||
| Revenue | 9,202 9,202 |
10%
10%
|
|
| Gross Profit | 5,436 5,436 |
15%
15%
|
|
| EBITDA | 2,985 2,985 |
9%
9%
|
EBIT (Operating Income) EBIT | 1,717 1,717 |
22%
22%
|
| Net Profit | -471 -471 |
153%
153%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Neutral
Accesswire
●
26 days ago
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / August 13, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Heal...
Neutral
Seeking Alpha
●
about one month ago
Bausch Health Companies (NYSE:BHC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Interim Chief Financial Officer Garen Sarafian - Investor Relations Conference Call Participants Glen Santangelo - Jefferies Mike Nedelcovych - TD Cowen Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Leszek Sulewsk...
Neutral
Accesswire
●
about one month ago
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAV...
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,270 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
